Common types of ADC linker reagents
ADC评论
December 21, 2022
An ADC linker reagent is a chemical compound that is used to connect a monoclonal antibody to a cytotoxic drug in the production of an
Month: December 2022
The relationship between fluorescent dyes and ADC drugs
ADC评论
December 19, 2022
Fluorescent dyes and ADC (antibody-drug conjugates) drugs are two different types of agents that are sometimes used in cancer treatment. Fluorescent dyes are compounds that
Advantages and limitations of CAR-T therapy
ADC评论
December 16, 2022
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of cancer treatment that involves the genetic modification of a patient’s own T-cells, a type of
Composition of antibody-drug conjugate
ADC评论
December 13, 2022
An antibody-drug conjugate (ADC) is a type of biopharmaceutical drug that is composed of an antibody and a cytotoxic drug. The purpose of an ADC
Principle of ADC conjugation technology
ADC评论
December 10, 2022
ADC, or antibody-drug conjugate, is a type of drug that combPrinciple ofines an antibody with a toxic drug in order to specifically target and kill
Pfizer and BioNTech countersued Moderna over COVID-19 vaccine technology patents
ADC评论
December 8, 2022
Recently, Pfizer of the United States and its German partner BioNTech countersued rival Moderna for the patent of the COVID-19 vaccine technology. broad” and “unenforceable”.
Antibody Drug Conjugates: Common Clinical Indications and Adverse Effects
Guest Post
December 2, 2022
Antibody-drug conjugates (ADCs) are a class of targeted biological agents that couple target-specific monoclonal antibodies with highly lethal cytotoxic drugs through specific linkers, using monoclonal
FDA approves first fecal microbe therapy
ADC评论
December 2, 2022
On November 30, 2022, Ferring Pharmaceuticals announced that its microbiome therapy REBYOTA® (RBX2660) was approved by the FDA, becoming the first approved fecal microbial therapy.
Therapeutic Window for Antibody-Drug Conjugates (ADC)
Guest Post
December 1, 2022
The development of antibody-drug conjugate (ADC) therapies has progressed rapidly in recent years, with 15 products approved worldwide. It is estimated that the global market
